Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 According ... by Power Source (Electric, Battery, Pneumatic), by Product ... Burr, Cart), by Application (Orthopedic, ENT, Oral, Thoracic, ... MarketsandMarkets, the global Powered Surgical Instruments Market is estimated ... in 2014 and is expected to grow at ...
(Date:11/26/2014)...  goBalto, Inc., the leading provider of cloud-based clinical ... of Red Herring,s Top 100 Global award. ... award in 2013, marking its emergence as a top ... Herring,s Top 100 Global list has become a mark ... Red Herring editors were among the first to recognize ...
(Date:11/26/2014)... , Nov. 25, 2014  Medtronic,s ... has been widely discussed in the media ... also creating a stronger leading player in one ... Kalorama Information.  The healthcare market research firm said ... will feature a diverse set of solutions spanning ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
... 2011 Actavis, an international generic pharmaceutical company, today ... Capsules, USP CII, an authorized generic of KADIAN®*. ... and has in-depth expertise in the development and manufacturing ... sales have grown 50% in the last 5 years ...
... Nov. 11, 2011 Panasonic Healthcare Group and United ... alliance with Cenegenics Medical Institute to implement some of ... and age management. Panasonic,s CardioHealth® Station continues to get ... of the best ways to reduce long-term healthcare costs ...
Cached Medicine Technology:Actavis Launches Generic KADIAN® Capsules in the U.S. 2Panasonic Unveils Relationship with Cenegenics Medical Institute Featuring CardioHealth Station 2Panasonic Unveils Relationship with Cenegenics Medical Institute Featuring CardioHealth Station 3Panasonic Unveils Relationship with Cenegenics Medical Institute Featuring CardioHealth Station 4
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance ... organization providing the adult demographic education and access ... navigate the rough seas of applying for Medicaid. Part ... the topic of Medicaid eligibility and proper planning, while ... applying for this coverage. , Senior Planning Services ...
(Date:11/26/2014)... Call 866-997-4948 (Us-Canada Toll Free) Tel: ... details on sales(at)researchmoz(dot)us , Researchmoz.us announces a new ... 2014" with deep study of the report on the ... blood sugar. The global glucose monitoring market has a ... number of diabetics in the world. Their numbers have ...
(Date:11/26/2014)... 26, 2014 Louisiana Back Institute, ... specialists in minimally invasive spine surgery, announces today ... the rapidly growing provider network of orthopedic spine ... coincides with the network’s continuing success providing the ... Louisiana residents who are suffering from orthopedic spine ...
(Date:11/26/2014)... who enter puberty early are at increased risk for ... linked with a number of factors associated with depression, ... to the researchers. Early puberty was also linked to ... and having friends who were prone to getting into ... an association between early puberty and these factors, it,s ...
Breaking Medicine News(10 mins):Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2
... combines spirituality with nature conservation by adopting an eco-friendly ... Ashram bury the dead and plant a sapling over ... flames as per the Hindu tradition. ,The ... fuel and enriches the environment through forestation. ...
... three sons, what Victoria Beckham is really wishing for, is a ... Jay Leno that she and hubby David Beckham will try to ... time shes hoping theyll be bringing back a bundle of pink ... wants a little girl, is because after all those boys in ...
... Dengue fever cases in Singapore, which is currently battling an ... temperatures soar, the city-state's environment minister said Monday . ... resources, told parliament there were 3,597 dengue fever cases in ... reported in the same period last year. ,He ...
... is all over between Kate Moss and Pete Doherty after ... , it seems that the waifish beauty will still pay ... will be the fifth one for the Babyshambles frontmans and ... said that the Brit supermodel is feeling betrayed, but she ...
... The rollercoaster ride of Dr.Mohammed Haneef, the man from Bangalore ... to pay a heavy price for a small act of indiscretion, ... used by his cousins, the key players in the failed Glasgow ... flight to India, two days after the Glasgow incident, Haneef has ...
... more than 90 per cent of women undergoing fertility treatments ... to stimulate their ovaries . ,This, the researchers state, ... but also that they may be exposing women to a ... cycle, women usually release one egg. The number is however ...
Cached Medicine News:Health News:Haneefs Visa Revoked by Australia 2
... (E2) is the most potent, naturally secreted ... by the ovary [1]. In the ovary, ... from estrone, a less potent estrogen derived ... in many body tissues. In men, small ...
... ADV is a Microparticle ... the quantitative determination of ... human serum or plasma ... Troponin-I values are used ...
... Estradiol (E2) is the most potent, ... estrogen produced by the ovary [1]. In ... [1,2], and from estrone, a less potent ... are interconverted in many body tissues. In ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
Medicine Products: